Updates on the latest developments at Hummingbird Diagnostics
Be among the first to get updates on the latest developments at Hummingbird Diagnostics by joining our mailing list for journalists.
Contact Hummingbird Diagnostics: firstname.lastname@example.org
- Hummingbird Diagnostics Publishes Study of miRisk as a Predictor of Immunotherapy Efficacy in Advanced-Stage NSCLC
- Hummingbird Diagnostics Announces Publication of Study on the Utility of miRisk
- Hummingbird Diagnostics awarded by Alzheimer’s Drug Discovery Foundation (ADDF)
Our recent publications
Learn more about genomic biomarkers and read our latest publications.
Are you a scientist interested in cooperative research and publication projects? Send an email to email@example.com.
A blood-based miRNA complementary diagnostic predicts immunotherapy efficacy in advanced stage NSCLC with PD-L1 TPS ≥50%
Rajakumar T, Horos R, Kittner P, Kahraman M, Sikosek T, et al.
Journal of Thoracic Oncology Clinical and Research Reports 2022
A blood-based miRNA signature with prognostic value for overall survival in advanced stage non-small cell lung cancer treated with immunotherapy
Rajakumar T, Horos R, Jehn J, Schenz J, Muley T, et al.
npj Precision Oncology 2022
Relevance of pre-analytical blood management on the emerging cardiovascular protein biomarkers TWEAK and HMGB1 and on miRNA serum and plasma profiling
Basso D, Padoan A, Laufer T, Aneloni V, Moz S, et al.
Clin Biochem. 2017
Open to new approaches
Meet Hummingbird Diagnostics
Take the opportunity to meet us and discuss your requests and projects.
Feel free to contact us if you have any questions or if you would like to arrange a meeting firstname.lastname@example.org